221 results about "Galactoside" patented technology

A method of enhancing the activity of lysosomal alpha-Galactosidase A (alpha-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.

The present invention relates to novel compounds and the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably galectin-3.

The present invention relates to novel compounds, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably a galectin-3.

A poultry feed composition including protein, vitamins and minerals, and a source of carbohydrates from the group consisting of soybean meals and corn supplemented with an alpha-galactosidase that catalyzes the degradation of the galactoside. The addition of the alpha-galactosidase increases the ratio of gain to feed, increases the amount of white meat, or decreases the amount of fat deposited during growth of a chicken fed the feed composition, relative to the chicken fed on an identical feed composition absent the alpha-galactosidase.

This invention provides to a novel gene encoding a protein aving the activity of beta-galactoside-alpha2,6-sialyltransferase.The gene of the invention encodes a protein which having the amino acid sequence of SEQ ID NO:1, or a protein having the amino acid sequence of SEQ ID NO:1 which have been modified by deletion, substitution or addition of at least one amino acid residue in said sequence, while maintaining substantially the same beta-galactoside-alpha2,6-sialyltransferase activity.The present invention uses said gene to further provide a vector for expressing a protein having the beta-galactoside-alpha2,6-sialyltransferase activity, host cells and a recombinant protein. The protein encoded by the gene of the invention does not have any substantial homology with known sialyltransferases, and in addition, the membrane binding region is located in the C-terminal unlike known sialyltransferases.

The invention discloses an effective part of stevia and the activity and the application thereof. The effective part mainly comprises stevioside category and flavone category which are obtained by extracting and separating from dried stevia leaves, wherein the sum of the percentage content of the stevioside components in the stevioside part is 5 to 100 percent (w / w), and the stevioside components mainly contains the stevioside, stevibioside, rebaudioside A, B, C, D, E, and F, dulcoside A and the derivative thereof, etc.; the sum of the percentage content of the flavone components in the flavone part is 5 to 100 percent (w / w), and the flavone components mainly contains luteolin, quercetin, luteolin-7-O-Beta-D-glucoside, apigenin-7-O-Beta-D-glucoside, quercitrin, quercetin-3-O-Beta-D-arabinoside, quercetin-3-O-(4-O-anti form-caffeoyl acyl-Alpha-L-rhamnose-(1 to 6)-Beta-D-galactoside) and the derivative thereof, etc., and 4, 5-dicaffeoylquinic acid and the derivative thereof, etc. The effective part has significant sugar-reducing and fat-reducing effects, can be used singly or combined with any other Chinese medicines and Western medicines or foods in any proportion, is used for preparing medicines or functional foods, and is used for treating hyperglycemia and hyperlipoidemia.

The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.

Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3. The novel compounds are defined by the general formula:

Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3. The novel compounds are defined by the general formula:

The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-β-xylopyranoside, quercetin-3-β-glucoside, quercetin-3-α-arabinopyranoside, 3′-methoxyquercetin-3-α-xylopyranoside, quercetin-3-O-(6″-p-coumaroyl)-β-galactoside, and quercetin-3-O-(6″-benzoyl)-β-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-α-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

The present invention relates to a compound of the general formula (I):The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.

The invention discloses a method for improving biosynthesis of levodopa. The method comprises the following steps of: (1) using SEQ ID No.1 and SEQ ID No.2 as the primers, using an E.coli BL21 strain as the template, amplifying and recycling so as to obtain a hpaBC gene segment, conducting double digestion on a pCDFDuet-1 plasmid and the hpaBC gene segment, connecting and preparing a recombinant plasmid pBET1; (2) introducing the recombinant plasmid pBET1 into host escherichia coli so as to obtain transformed host cells; and (3) selecting the transformed host cells so as to obtain a levodopa production engineering bacteria single colony, taking 1ml of the levodopa production engineering bacteria single colony and putting into 100ml of a first culture medium, cultivating and measuring OD600, adding an isopropyl-beta-D-sulfo-pyran galactoside water solution and ascorbic acid, continuing cultivating and measuring the content of the levodopa. By utilizing the method disclosed by the invention, the output of the levodopa is increased, the production cost is lowered, and the operation process is simplified.

The invention discloses a complex enzyme preparation improving broiler chicken breeding performance. The complex enzyme preparation is characterized by being prepared from a carrier, xylanase, cellulase, alpha-galactosidase, beta-mannase, pectinase, amylase, lipase and protease, wherein xylanase, cellulase, alpha-galactosidase, beta-mannase, pectinase, amylase, lipase and protease are added in the carrier. In each gram of the complex enzyme preparation improving broiler chicken breeding performance, the activity of xylanase is 1000-10000 U, the activity of alpha-galactosidase is 2-40 U, the activity of cellulase is 100-3000 U, the activity of beta-mannase is 100-2500 U, the activity of pectinase is 100-3000 U, the activity of amylase is 100-3000 U, the activity of lipase is 50-2000 U, and the activity of protease is 1000-10000 U. According to application of the complex enzyme preparation improving broiler chicken breeding performance in broiler chicken feed, 100-1000 g of the complex enzyme preparation is added in each ton of complete feed. The complex enzyme preparation can generate the emergy of 25-85 kcal / kg, effectively degrade antinutritional factors such as soluble xylan, mannan and alpha-galactoside, increase the digestion rate of nutrients such as protein and amino acid, improve broiler chicken productivity and lower breeding cost.

The invention relates to a genetic engineered bacterium which contains a recombinant plasmid pET28a-GMAS, is 6585 bp in a plasmid size, is 1308 bp in a fragment size of a GMAS, is named as Escherichia coli and has a kanapenecilin resistance. Genes of the [gamma]-glutamylmethylamine synthetase are inducibly expressed by isopropylsulpho-[beta]-D-galactoside. The genetic engineered bacterium has a capability of biologically synthesizing theanine. By means of glutamic acid and ethylamine as substrates, a method in the invention is simple in operation method, is convenient to control in production, is high in conversion and production efficiency of the theanine and has an excellent industrial application prospect.

The invention discloses a high efficiency turning glycosyl beta-galactosidase gene. The genes are gained by enterobacter cloacae B5 CGMCC No.1401 gene set DNA under PCR amplification. The whole length of gene nucleotide sequence is 3090 basic groups, and coding 1029 amino acid. The recombinase features are that enzyme is quart-subunit albumen; polymer molecular weight are 391kD; mono subunit are 97.8kD; the enzyme to lactose Km value is 0.32mmol / L, Vmax is 210.70umol / (L.min); and it to onitrophenol-beta-D-galactoside Km value is close to 0; its optimum reaction temperature is 35 centigrade degree; the pH value is from 6.5-9.5; it can be stored at least two months at room temperature; oligomerization galactose yield is 55%; receptor substrate specificity of the enzyme turning glycosyl is very wild; it can used to compose multi galactoside compounds. The gained enzyme gene can be used to modify gene to gain new beta-galactoside synthetase, and improve its combined efficiency fundamentally.

The present invention relates to novel compounds and the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably galectin-3.

The invention discloses choline eutectic solvents, a preparation method and an application in extraction of flavone C-glycoside of flos trollii. The choline eutectic solvents have the expression: [N(CH)33CH2CH2OH]+[X.zY]- and is prepared from choline bromide or choline chloride and ZnCl2, SnCl2 or AlCl3 through mixing in a certain mole ratio, wherein when X is Br, Y is ZnCl2 or SnCl2; when X is Cl, Y is AlCl3. By means of the provided choline eutectic solvents, three important flavone C-glycosides, namely, orientin, orientin-2''-O-beta-L-galactoside and vitexin in the flos trollii can be efficiently and selectively extracted; compared with conventional extraction with methanol solvents, the extraction rate of orientin, orientin-2''-O-beta-L-galactoside and vitexin can be improved, few impurities exist in an extract, silica gel columns are not required to be repeatedly used for separation when the extract serving as the raw material is used for preparing monomers of orientin, orientin-2''-O-beta-L-galactoside and vitexin, the separation and purification steps can be greatly reduced, and the separation and purification cost can be reduced.

The present invention discloses a method for simultaneously preparing hyperin and isorhammetin-3-O-galactoside control products. Said method includes the following steps: (1) placing Chinese medicinal material evodia in a container, adding solvent to make extraction with reflux; (2) filtering evodia extract, reduced pressure concentrating to obtain extractum, adding water to dissolve it, then successively using petroleum ether, chloroform and ethyl acetate to make extraction; (3). using column chromatographic process to purify the ethyl acetate extracted portion twice; and (4). combining chromatographic eluents, concentrating, recrystallizing so as to obtain the invented two control products of hyperin and isorhamnetin-3-O-galactoside. Said invention is simple, and can simultaneously prepare hyperin and isorhamnetin-3-O-galactoside pure products whose purity can be above 98%.

The invention relates to a chromogenic media of salmonella, a detection kin and a detection method, which belongs to safety monitoring field of food microorganisms. The detection kin is composed of chromogenic media of mixed chromogenic substrates M-galactoside added with bacteria-specific enzyme of 0.1 to 0.5 grams, buffered peptone water medium of enrichment fluid A, and brilliant green enrichment fluid B of sodium tetrathionate. In the time of detecting, a food sample is pretreated, the enrichment fluids A and B are sequentially utilized to perform enriched culture, the secondary enrichment fluids are finally inoculated to be cultured on the chromogenic media, and the appearance of basic fuchsin bacterial colony which is smooth, slightly convex, and uniform in the edge and of which the diameter is 1 to 3 millimeters proves the existence of the salmonella in the sample. The chromogenic media is low in costs, and the detection kin is simple in configuration. The detection method has the advantages of high detecting sensibility, short cycle, strong operability and applicability for the treatment of samples of high flux, which is easy in industrialization production and capable of being widely applied in the fields of food sanitation, environmental monitoring and the like.

The invention discloses prebiotics-added formula milk powder suitable for premature infants and infants with low birth weight and a preparation method thereof and belongs to the technical field of foods. The prebiotics-added formula milk powder is prepared from the following raw materials: whole milk or whole milk powder or skim milk powder, desalted whey powder, whey protein powder, mixed prebiotics, mixed edible vegetable oil, docosahexenoic acid, arachidonic acid, OPO structural fat, medium chain triglyceride, vitamin premix, mineral premix, inositol, choline bitartrate, taurine, L-carnitine tartrate and nucleotide, wherein the mixed prebiotics are prepared by mixing two or more than two of galactooligosaccharide, fructo-oligosaccharide, trans-galactoside oligosaccharide, lactosucrose, inulooligosaccharide and lactitol. The milk powder reaches nutritional ingredient balance, immune ingredient balance and acid-base balance, is more close to the ingredients of breast milk, can promote proliferation of beneficial bacteria in the intestine, improve absorption of calcium and magnesium and meet the energy requirements of the infants, and has an effect of promoting healthy development of organs.

The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-β-xylopyranoside, quercetin-3-β-glucoside, quercetin-3-α-arabinopyranoside, 3′-methoxyquercetin-3-α-xylopyranoside, quercetin-3-O-(6″-p-coumaroyl)-β-galactoside, and quercetin-3-O-(6″-benzoyl)-β-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-α-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-β-xylopyranoside, quercetin-3-β-glucoside, quercetin-3-α-arabinopyranoside, 3′-methoxyquercetin-3-α-xylopyranoside, quercetin-3-O-(6″-p-coumaroyl)-β-galactoside, and quercetin-3-O-(6″-benzoyl)-β-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-α-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.

There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C′ channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A′ channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C′ channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of α-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A′ channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of α-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond, X represents or —CHA(CHOH)nY or —P(═0)(0−)0CH2(CH0H)mY, in which Y represents CHB1B2, n represents an integer from 1 to 4, m represents 0 or 1, A årepresents hydrogen, one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or one of B1 and B2 represents hydroxyl and the other represents phenyl, in addition, when n represents 4, then A together with one of B1 and B2 together forms a single bond and the other of B1 and B2 represents H, OH or OSO3H and pharmaceutically acceptable salts thereof; the compounds of formula I are indicted for use in the treatment of a virus, microbial infection, parasite, an autoimmune disease, cancer, allergy or asthma

The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.

The invention encompasses a novel method of treating an inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases, such as rheumatoid arthritis, and their clinical symptoms. The inventors have made the discovery that the activity of galectin-3, a β-galactoside-binding lectin known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of an inflammatory disease, such as rheumatoid arthritis, may be alleviated by administering a compound that inhibits the activity of galectin-3.

The present invention relates to novel compounds prepared from readily accessible 3-O-propargyl-D-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligands in a mammal, wherein said galectin is preferably a galectin-3. The novel compounds are defined by the general formula (I).

Novel synthesis routes for preparation of thiodigalactosides and intermediates are presented. The method includes the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corresponding thiol in situ, which in turn is directly reacted with a 3-azido-galactosyl bromide resulting in the 3,3′-di-azido-thio-di-galactoside before the thiol has a chance to reduce the azido 10 group. Hence, in situ formation of the 3-azido-galactosyl thiol from the thiouronium salt is essential in the synthesis procedure, because any other method that generate the thiol separately results in extensive unwanted azide reduction.

The present invention provides an extremely useful and novel β-galactoside-α2,6-sialyltransferase having an optimum reaction pH in a neutral to alkaline range, and a nucleic acid encoding the sialyltransferase. The present invention further provides a vector carrying a nucleic acid encoding the sialyltransferase, and a host cell transformed with the vector, as well as a method for producing a recombinant β-galactoside-α2,6-sialyltransferase.